Natco Pharma Limited

Natco Pharma Limited

Natco Pharma Limited has informed the Exchange regarding Outcome of Board Meeting held on July 08, 2026, where the Board of Directors approved to acquire additional shareholding in Adcock Ingram Holdings Proprietary Limited, increasing its stake from 35.75% to 49%. The acquisition valued at ₹ 1,069 crores will take NATCO's shareholding in Adcock Ingram from 35.75% to 49%. Adcock Ingram has delivered a topline of US$ 423 million with an EBITDA of ~US$ 59 million for the period ending 9 months on March 31, 2026.

Natco Pharma Limited

Natco Pharma Limited has announced a change in management with Mr. Gnanadeva Chalapathy Gudipati being designated as Senior Vice President - Analytical Research & Development and Mr. Madhava Rao Karicherla as Vice President – Formulation Research & Development, effective July 6, 2026.

Natco Pharma Limited

Natco Pharma Limited has informed the Exchange about the retirement of Mr. Nadella Malleswara Rao, Vice President - Operations, Pharma Division Kothur, effective June 30, 2026.

Natco Pharma Limited

Natco Pharma Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015. The Trading Window for dealing in the securities of the Company will remain closed for Directors, Designated Persons, their immediate relatives, and all other connected persons from July 1, 2026, to 48 hours after the declaration of the Unaudited Financial Results for the quarter ending June 30, 2026.